Mirati and Boehringer partner to test KRAS-KRAS combo

Mirati and Boehringer have teamed up to test the hypothesis that two KRAS inhibitors are better than one after preclinical data suggested blocking the oncogene in different ways may produce complementary effects.

The companies will test the G12C mutation-selective inhibitor MRTX849 from Mirati Therapeutics Inc. (NASDAQ:MRTX) in combination with BI 1701963, a SOS1:pan-KRAS inhibitor from Boehringer Ingelheim GmBH, in non-small cell lung cancer (NSCLC) and colorectal cancer patients harboring KRAS G12C mutations. Mirati will sponsor the clinical trial and the companies will share the costs. ...